Judah Frommer
Stock Analyst at Morgan Stanley
(3.11)
# 1,115
Out of 4,832 analysts
184
Total ratings
58.96%
Success rate
5.05%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $19.63 | +119.11% | 2 | May 9, 2025 | |
| BPMC Blueprint Medicines | Assumes: Equal-Weight | $120 → $100 | $99.41 | +0.60% | 1 | Mar 20, 2025 | |
| ABVX ABIVAX Société Anonyme | Assumes: Equal-Weight | $12 | $6.04 | +98.68% | 1 | Mar 20, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $8.18 | +193.40% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $26.84 | -18.03% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $3.27 | +83.49% | 2 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Equal-Weight | $31 | $17.28 | +79.40% | 1 | Nov 21, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $58.25 | +81.97% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $13.04 | +168.40% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.66 | +388.72% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $0.87 | +245.46% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $4.82 | +729.88% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.05 | +1,138.10% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $29.88 | +0.40% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $8.93 | +157.56% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $46.39 | +7.78% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $36.20 | +289.50% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.16 | +1,020.69% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $1.41 | +538.30% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $18.75 | +17.33% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.40 | +29.75% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $5.79 | +38.17% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $11.28 | +307.80% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $0.78 | +796.63% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $12.81 | +329.35% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $65.71 | -30.00% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $87.44 | -43.96% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $999.03 | -62.96% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $73.84 | -58.02% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $70.80 | +7.34% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $86.85 | +109.56% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $85.71 | +24.84% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $113.94 | -16.62% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $21.72 | -17.13% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $101.69 | +14.07% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $107.85 | -64.77% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $158.47 | -86.12% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $67.49 | -48.14% | 9 | Apr 29, 2020 |
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $19.63
Upside: +119.11%
Blueprint Medicines
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $120 → $100
Current: $99.41
Upside: +0.60%
ABIVAX Société Anonyme
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $12
Current: $6.04
Upside: +98.68%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $8.18
Upside: +193.40%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $26.84
Upside: -18.03%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $3.27
Upside: +83.49%
Apellis Pharmaceuticals
Nov 21, 2024
Initiates: Equal-Weight
Price Target: $31
Current: $17.28
Upside: +79.40%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $58.25
Upside: +81.97%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $13.04
Upside: +168.40%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.66
Upside: +388.72%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $0.87
Upside: +245.46%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $4.82
Upside: +729.88%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.05
Upside: +1,138.10%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $29.88
Upside: +0.40%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $8.93
Upside: +157.56%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $46.39
Upside: +7.78%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $36.20
Upside: +289.50%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.16
Upside: +1,020.69%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $1.41
Upside: +538.30%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $18.75
Upside: +17.33%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.40
Upside: +29.75%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $5.79
Upside: +38.17%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $11.28
Upside: +307.80%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $0.78
Upside: +796.63%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $12.81
Upside: +329.35%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $65.71
Upside: -30.00%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $87.44
Upside: -43.96%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $999.03
Upside: -62.96%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $73.84
Upside: -58.02%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $70.80
Upside: +7.34%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $86.85
Upside: +109.56%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $85.71
Upside: +24.84%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $113.94
Upside: -16.62%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $21.72
Upside: -17.13%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $101.69
Upside: +14.07%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $107.85
Upside: -64.77%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $158.47
Upside: -86.12%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $67.49
Upside: -48.14%